Main image Main image

Cend Therapeutics in the News

January 1, 2018

Click here for more information.

November 26, 2017

DrugCendR will present at the Biotech Showcase and schedule one-to-one meetings during the conference. Investors who wish to meet with Harri Jarvelainen for a one-to-one meeting should send direct inquiry to the company.


November 21, 2017

Saira Ramasastry is a seasoned biotech industry insider with over 20 years of transaction and advisory experience. She serves on the Industry Advisory Board of the Michael J Fox Foundation for Parkinson’s Research, Chief Business Advisor for the European Prevention of Alzheimer’s Dementia (EPAD) consortium, as well as a Special Advisor for the G8 Health Initiatives. Previously she helped found and establish the leading life sciences franchise on Wall Street at Merrill Lynch and was responsible for emerging biotech coverage for over a decade. In addition, Saira has worked in M&A and Restructuring at Wasserstein Perella. Saira has a B.A. in Economics with Honors and Distinction from Stanford University, and advanced degrees in Management Science & Engineering from Stanford University and Management Studies from the University of Cambridge. Saira is a Silicon Valley’s 40 Under 40 (2012), Health Innovator Fellow of the Aspen Institute, and recently named a top global life sciences advisor by Finance Monthly and CorporateLiveWire.

For more information.



INNOVATION Kyoto 2016 LPs Completes Strategic Investment in DrugCendR Inc.

(Kyoto, Japan / La Jolla, CA) – INNOVATION Kyoto 2016 Limited Liability Partnership (“KYOTO-iCAP 1st Fund”), and Kyoto University Innovation Capital Co., Ltd. (the general partner. Headquarters: Sakyo-ku, Kyoto City; CEO: Koji Murota; “Kyoto-iCAP”) and DrugCendR Inc. (Headquarters: La Jolla, CA, US; President and CEO: Erkki Ruoslahti; “DrugCendR”) today jointly announced that it has concluded a multimillion-dollar investment in DrugCendR, to accelerate the global development of DrugCendR’s breakthrough tumor penetrating technology.

“I am delighted to announce the completion of the strategic investment in DrugCendR Inc. We, Kyoto-iCAP, will continue to support the development of DrugCendR’s technologies in the long term.”said Koji Murota, CEO of Kyoto-iCAP.

“This investment into DrugCendR Inc. by Kyoto-iCAP and Kyoto University will allow us to complete our ongoing phase 1 clinical trial on the lead compound of the company” stated Dr. Erkki Ruoslahti, M.D., Ph.D., President and CEO of DrugCendR. “The strategic relationship with the fund and Kyoto University, a preeminent university in the world, will be important for us into the future. We will also collaborate with clinical researchers led by Dr. Yoshiharu Sakai, M.D., Ph.D., Professor of Surgery on clinical studies the university is uniquely equipped to perform. We hope to provide new treatment options for cancer patients in the US, Japan and elsewhere in the world.”

Concurrent with the investment, DrugCendR will initiate non-clinical and clinical research collaboration with Kyoto University. Professor Yoshiharu Sakai, M.D., Ph.D., Gastrointestinal Surgery, Department of Surgery, Kyoto University and Associate Professor Kazutaka Obama, M.D., Ph.D. will lead the collaboration for Kyoto University.